Internal Med

sponsor

Your Unread Messages

Hello, Mary O'connor
Manage E-mail  |  Logout
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Seiler T et al. – High response rates and durable remissions have been seen with both 90Y–ibritumomab tiuxetan and 131I–tositumomab. However, refractoriness to immunochemotherapy still remains a problem, especially in relapsed disease. Several novel targeted agents show encouraging activity in follicular lymphoma. This review will focus on current treatment strategies in this disease.

Today in Allergy/Immunology...keeping you current

Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Archives of Neurology, 11/24/09

Associations between decay-accelerating factor polymorphisms and allergic respiratory diseases
Clinical and Experimental Allergy, 11/24/09

Pulmonary periarterial inflammation in fatal asthma
Clinical and Experimental Allergy, 11/24/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address